Date: 2016-09-15
Type of information: Clinical research agreement
Compound: TIL (tumor infiltrating lymphocyte) products
Company: Lion Biotechnologies (USA - CA) Karolinska University Hospital (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: cell therapy/immunotherapy product
Disease: glioblastoma, pancreatic cancer
Details: * On September 15, 2016, Lion Biotechnologies announced that it has entered into a clinical trials agreement to sponsor two clinical studies in glioblastoma and pancreatic cancer at the Karolinska University Hospital in Sweden. Under the terms of the clinical trials agreement, Lion will fund two clinical studies in glioblastoma and pancreatic cancer to be conducted at the Karolinska University Hospital in which TIL (tumor infiltrating lymphocyte) is manufactured using a specific combination of cytokines licensed from PolyBioCept.
Financial terms:
Latest news:
